Brief: SAB Biotherapeutics To Present New Data At ISIRV Options XI Conference On SAB-185's Effectiveness Against Multiple COVID-19 Variants
23/09/2022 14:03
Sept 23 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS TO PRESENT NEW DATA AT ISIRV OPTIONS
XI
CONFERENCE ON SAB-176 PHASE 2A INFLUENZA TRIAL AND SAB-185’S
EFFECTIVENESS AGAINST MULTIPLE COVID-19 VARIANTS
* SAB BIOTHERAPEUTICS - WILL CONDUCT ORAL PRESENTATION ON
EFFICACY
AND SAFETY OF SAB-176 ON THURSDAY, SEPT 29
Source text for Eikon: ID:nGNX6VMrYv
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies